IBDEI02L ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,660,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,661,0)
 ;;=Z85.831^^2^27^29
 ;;^UTILITY(U,$J,358.3,661,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,661,1,3,0)
 ;;=3^Personal history of malignant neoplasm of soft tissue
 ;;^UTILITY(U,$J,358.3,661,1,4,0)
 ;;=4^Z85.831
 ;;^UTILITY(U,$J,358.3,661,2)
 ;;=^5063445
 ;;^UTILITY(U,$J,358.3,662,0)
 ;;=Z85.71^^2^27^1
 ;;^UTILITY(U,$J,358.3,662,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,662,1,3,0)
 ;;=3^Personal history of Hodgkin lymphoma
 ;;^UTILITY(U,$J,358.3,662,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,662,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,663,0)
 ;;=Z85.830^^2^27^30
 ;;^UTILITY(U,$J,358.3,663,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,663,1,3,0)
 ;;=3^Personal history of malignant neoplasm of bone
 ;;^UTILITY(U,$J,358.3,663,1,4,0)
 ;;=4^Z85.830
 ;;^UTILITY(U,$J,358.3,663,2)
 ;;=^5063444
 ;;^UTILITY(U,$J,358.3,664,0)
 ;;=Z85.820^^2^27^2
 ;;^UTILITY(U,$J,358.3,664,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,664,1,3,0)
 ;;=3^Personal history of malignant melanoma of skin
 ;;^UTILITY(U,$J,358.3,664,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,664,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,665,0)
 ;;=Z85.828^^2^27^31
 ;;^UTILITY(U,$J,358.3,665,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,665,1,3,0)
 ;;=3^Personal history of malignant neoplasm of skin NEC
 ;;^UTILITY(U,$J,358.3,665,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,665,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,666,0)
 ;;=Z85.840^^2^27^32
 ;;^UTILITY(U,$J,358.3,666,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,666,1,3,0)
 ;;=3^Personal history of malignant neoplasm of eye
 ;;^UTILITY(U,$J,358.3,666,1,4,0)
 ;;=4^Z85.840
 ;;^UTILITY(U,$J,358.3,666,2)
 ;;=^5063446
 ;;^UTILITY(U,$J,358.3,667,0)
 ;;=Z85.841^^2^27^33
 ;;^UTILITY(U,$J,358.3,667,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,667,1,3,0)
 ;;=3^Personal history of malignant neoplasm of brain
 ;;^UTILITY(U,$J,358.3,667,1,4,0)
 ;;=4^Z85.841
 ;;^UTILITY(U,$J,358.3,667,2)
 ;;=^5063447
 ;;^UTILITY(U,$J,358.3,668,0)
 ;;=Z85.848^^2^27^34
 ;;^UTILITY(U,$J,358.3,668,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,668,1,3,0)
 ;;=3^Personal history of malignant neoplasm of prt nervous tissue
 ;;^UTILITY(U,$J,358.3,668,1,4,0)
 ;;=4^Z85.848
 ;;^UTILITY(U,$J,358.3,668,2)
 ;;=^5063448
 ;;^UTILITY(U,$J,358.3,669,0)
 ;;=Z85.850^^2^27^35
 ;;^UTILITY(U,$J,358.3,669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,669,1,3,0)
 ;;=3^Personal history of malignant neoplasm of thyroid
 ;;^UTILITY(U,$J,358.3,669,1,4,0)
 ;;=4^Z85.850
 ;;^UTILITY(U,$J,358.3,669,2)
 ;;=^5063449
 ;;^UTILITY(U,$J,358.3,670,0)
 ;;=Z85.858^^2^27^36
 ;;^UTILITY(U,$J,358.3,670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,670,1,3,0)
 ;;=3^Personal history of malignant neoplasm of endocrine glands
 ;;^UTILITY(U,$J,358.3,670,1,4,0)
 ;;=4^Z85.858
 ;;^UTILITY(U,$J,358.3,670,2)
 ;;=^5063450
 ;;^UTILITY(U,$J,358.3,671,0)
 ;;=N17.1^^3^28^2
 ;;^UTILITY(U,$J,358.3,671,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,671,1,3,0)
 ;;=3^Acute kidney failure w/ acute cortical necrosis
 ;;^UTILITY(U,$J,358.3,671,1,4,0)
 ;;=4^N17.1
 ;;^UTILITY(U,$J,358.3,671,2)
 ;;=^5015599
 ;;^UTILITY(U,$J,358.3,672,0)
 ;;=N17.2^^3^28^3
 ;;^UTILITY(U,$J,358.3,672,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,672,1,3,0)
 ;;=3^Acute kidney failure w/ medullary necrosis
 ;;^UTILITY(U,$J,358.3,672,1,4,0)
 ;;=4^N17.2
 ;;^UTILITY(U,$J,358.3,672,2)
 ;;=^5015600
 ;;^UTILITY(U,$J,358.3,673,0)
 ;;=N17.8^^3^28^1
 ;;^UTILITY(U,$J,358.3,673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,673,1,3,0)
 ;;=3^Acute Kidney Failure NEC
 ;;
 ;;$END ROU IBDEI02L
